Pyruvate kinase deficiency

Red blood cells rely on glycolysis to make the energy needed to maintain their structure and function. Pyruvate kinase helps with this process. When it works poorly, red cells have a shortened lifespan, causing hemolytic anemia.

Severity ranges from mild anemia to serious illness in infancy or a need for regular transfusions. The hemoglobin level is only part of the picture; symptoms, growth and complications also guide care.

Disease-causing variants in both copies of PKLR usually cause the condition. It is typically inherited in a recessive pattern, with carrier parents often having no symptoms.

The precise variants can influence enzyme function and treatment response, but genotype alone does not perfectly predict the disease course. This inherited red-cell disorder is different from low pyruvate kinase activity secondary to another illness.

Possible effects include fatigue, jaundice, an enlarged spleen and gallstones. Severe newborn jaundice may need urgent treatment. Anemia can become worse during certain illnesses or periods of increased demand.

Iron overload can develop even in people who are not regularly transfused, as well as in people receiving repeated transfusions. Iron assessment is therefore relevant across different levels of apparent disease severity.

Transfusion decisions consider symptoms and overall health. Iron chelation may be used when iron accumulates, with monitoring of the liver and other organs as appropriate.

Splenectomy can reduce red-cell destruction in selected patients, but it does not correct the enzyme defect. It carries long-term infection and clotting risks and may not eliminate transfusion needs.

Mitapivat, marketed as Pyrukynd, is FDA approved for hemolytic anemia in adults with pyruvate kinase deficiency. It activates pyruvate kinase, but response is not universal. The prescribing information and the person’s genetic and clinical findings guide assessment; adult approval should not be generalized to children.

Allogeneic transplantation has been used in a small number of severely affected people. Its potential to correct blood production has to be weighed against graft failure, graft-versus-host disease and treatment-related death. It is not routine treatment for everyone needing transfusions.

Care may include blood tests, iron imaging, transfusion appointments or daily medicine. The burden can be substantial even when anemia is described as moderate, and fatigue does not always track closely with a single blood result.

People considering spleen surgery or transplant need time to discuss lasting effects, infection precautions, fertility and follow-up. The balance changes with disease severity and available treatments; another person’s course cannot predict their own.

When transplantation is selected, the cells come from a suitable related or unrelated donor. Relatives require clinical and genetic assessment as well as tissue matching.

For most treatment decisions, the immediate question is how to manage anemia and its complications. A registry donor is a possible resource for selected transplant candidates, not the usual treatment for pyruvate kinase deficiency.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?